Brown University

brown.edu

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

281

Active

56

Phase 3

9

Total enrollment

360,717

Pipeline matrix

Showing 29 of 29 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Arm I Carboplatin, Paclitaxel, Pembrolizumab—————1
Arm II Carboplatin, Paclitaxel, Cetuximab—————1
Arm III Pembrolizumab—————1
Hydroxyurea—————1
Nivolumab—————4
Ipilimumab—————2
Lenalidomide—————2
Doxazosin————2
Regular Human Insulin then Placebo—————1
ASP-1929 photoimmunotherapy—————1
Tafasitamab—————1
Polatuzumab vedotin—————1
Glofitamab—————1
Obinutuzumab—————1
Trastuzumab deruxtecan—————1
Mosunetuzumab—————1
Probenecid Oral—————1
Dexamethasone—————1
Ipilumumab—————1
Rucaparib—————1
Copanlisib—————1
THC-dominant cannabis—————1
CBD-dominant cannabis—————1
Cannabis placebo—————1
Alcohol—————1
Alcohol placebo—————1
Gemtuzumab Ozogamicin—————1
yttrium-90 radioembolization—————1
ACM-CpG—————1

Next readouts

  • 2019-03
  • 2023-09-26
  • 2025-05-05
  • 2026-06
  • 2026-06
  • 2026-06-01
  • 2026-08-31
  • 2026-09-01
  • 2026-09-01
  • 2026-12-31

Top conditions

  • Alcohol Drinking13
  • Depression11
  • Alcohol Abuse10
  • HIV9
  • Alcohol Use Disorder8
  • Anxiety7
  • Prostate Cancer7
  • Smoking Cessation7

Frequently asked questions about Brown University

How many clinical trials does Brown University have on ClinicalTrials.gov?
Brown University is listed as the lead sponsor on 281 clinical trials in ClinicalTrials.gov, 56 of which are currently active (recruiting, enrolling, or ongoing).
How many of Brown University's trials are in Phase 3?
9 of Brown University's trials are in Phase 3, spread across 29 active drug programs.
What therapeutic areas does Brown University focus on?
Brown University's most-studied conditions on ClinicalTrials.gov are Alcohol Drinking, Depression, Alcohol Abuse, HIV, Alcohol Use Disorder.
When are Brown University's next clinical trial readouts?
Brown University has 10 upcoming primary-completion readouts tracked here; the soonest is “Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma”, expected around 2019-03.